Showing 4621-4630 of 8890 results for "".
- Almirall Appoints Mercedes Diz as VP, Corporate Strategyhttps://practicaldermatology.com/news/almirall-appoints-mercedes-diz-as-vp-corporate-strategy/2461449/Almirall named Mercedes Diz as its VP Corporate Strategy. Diz will also join Almirall's Management Board of Directors, effective December 1. Diz joined Almirall in 2002 and, since 2021, has held the position of Senior Director of Corporate Str
- Almirall Joins Project Aimed at Giving Clinical Trial Data Back to Study Participantshttps://practicaldermatology.com/news/almirall-joins-project-aimed-at-giving-clinical-trial-data-back-to-study-participants/2461446/Almirall is participating in FACILITATE (FrAmework for ClInicaL trIal participants’ daTA reutilization for a fully Transparent and Ethical ecosystem), a patient-driven Innovative Medicines Initiative (IMI) project that aims to create a framework for access and reutilization of clinical tria
- CPP Launches Network of Physician-led Medical Aesthetics Clinics Across UShttps://practicaldermatology.com/news/cpp-launches-network-of-physician-led-medical-aesthetics-clinics-across-us/2461442/Cosmetic Physician Partners Inc. ("CPP") is pleased to announce its official launch in the US with the closing of its 10th medical aesthetics clinic. Led by Dr. A. Jay Burns, Dr. Joel L. Cohen, Matt and Kathy Taranto and Dan Schacter, CPP is a partnership designed to provide physician o
- Crown’s Patented Xycrobe Technology Supports a Healthy Skin Microbiomehttps://practicaldermatology.com/news/crowns-patented-xycrobe-technology-supports-a-healthy-skin-microbiome/2461440/Crown Aesthetics’ BIOJUVE regimen, which incorporates the patented Xycrobe technology, supports a healthy skin environment, promotes increased skin hydration, decreases redness, regulates sebum production and reduces the appearance of signs of aging such as fine lines and photodam
- FDA Clears the Accure Laser System for the Treatment of Mild to Severe Inflammatory Acne Vulgarishttps://practicaldermatology.com/news/fda-clears-the-accure-laser-system-for-the-treatment-of-mild-to-severe-inflammatory-acne-vulgaris/2461439/The FDA has cleared Accure Acne Inc's Accure Laser System to treat mild to severe inflammatory acne vulgaris. The Accure Laser System builds upon the unique selectivity of the 1726nm laser wavelength, adding proprietary technology to precisely control thermal gradient depth. This technology b
- Laser Could Prevent UV Radiation-Induced Damage to Skinhttps://practicaldermatology.com/news/laser-could-prevent-uv-radiation-induced-damage-to-skin/2461438/Incidence rates of squamous cell carcinomas (SCCs) are increasing, particularly in high-risk populations, including fair-skinned or immunosuppressed individuals. Few therapeutic options exist to prevent sunlight-induced skin cancer despite rising incidence rates. A recent study determined that ab
- Castle's DecisionDx-SCC Provides Clarity in Assessing Risk SCC Spread in Challenging Staging Situationshttps://practicaldermatology.com/news/castles-decisiondx-scc-provides-clarity-in-assessing-risk-scc-spread-in-challenging-staging-situations/2461436/Castle Biosciences, Inc.’s DecisionDx-SCC test provides objective, independent and significant risk-stratification for cutaneous squamous cell carcinoma (cSCC) tumors with uncertainty in differentiation status. The data were shared in an oral presentation given at the Americ
- CeraVe Establishes Fund at Howard University to Address Lack of Diversity in Skincare Clinical Researchhttps://practicaldermatology.com/news/cerave-establishes-fund-at-howard-university-to-address-lack-of-diversity-in-skincare-clinical-research/2461435/To help close the existing racial inequity gap in dermatological research, CeraVe is establishing a fund at Howard University to help its faculty further their expertise and build the infrastructure needed to conduct clinical trials with a focus on skin of color. Located in Washing
- AD News: Alphyn Biologics Completes First Cohort of Phase2a Clinical Trial of Topical Therapyhttps://practicaldermatology.com/news/ad-news-alphyn-biologics-completes-first-cohort-of-phase2a-clinical-trial-of-topical-therapy-1/2461432/Alphyn Biologics completed the first cohort of its Phase2a clinical trial of AB-101a, a topical therapeutic candidate for mil
- Supergoop! Founder & CEO Named Ernst & Young LLP’s Entrepreneurs of the Year for 2022https://practicaldermatology.com/news/supergoop-founder-ceo-named-ernst-young-llps-entrepreneurs-of-the-year-for-2022/2461430/Holly Thaggard and Amanda Baldwin of Supergoop! are Ernst & Young LLP’s Entrepreneurs of the Year for 2022. The Entrepreneur of the Year program honors and elevates entrepreneurs who think big and act boldly to change our world for nearly four decades.